About OncoDNA
OncoDNA is a company based in Charleroi (Belgium) founded in 2012. OncoDNA has raised $44.53 million across 6 funding rounds from investors including Copenhagen Airport, Swisscanto and Ackermans & van Haaren. OncoDNA has completed 1 acquisition, including Bio Sequence. OncoDNA offers products and services including OncoDEEP Kit, OncoSELECT Kit, OncoCDI, and OncoKDM. OncoDNA operates in a competitive market with competitors including Denali Therapeutics, Inscripta, MiRagen, Poseida Therapeutics and Juno Therapeutics, among others.
- Headquarter Charleroi, Belgium
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oncodna S.A.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$44.53 M (USD)
in 6 rounds
-
Latest Funding Round
$127.79 K (USD), Grant
Nov 01, 2023
-
Investors
Copenhagen Airport
& 15 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OncoDNA
OncoDNA offers a comprehensive portfolio of products and services, including OncoDEEP Kit, OncoSELECT Kit, OncoCDI, and OncoKDM.
Kit for comprehensive genomic profiling of tumors.
Kit for detecting biomarkers in liquid samples.
Platform for analyzing clinical data in oncology research.
Tool for interpreting genomic data in precision medicine.
People of OncoDNA
Unlock access to complete
Unlock access to complete
Funding Insights of OncoDNA
OncoDNA has successfully raised a total of $44.53M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $127.79 thousand completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OncoDNA
OncoDNA has secured backing from 16 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Copenhagen Airport, Swisscanto and Ackermans & van Haaren.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A European life sciences venture capital investor is operated.
|
Locked | Locked | Locked | |
|
VC & PE fund
|
Locked | Locked | Locked | |
|
Buyouts are pursued by SRIW as a private equity firm.
|
Locked | Locked | Locked |
Investor details for OncoDNA
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OncoDNA
OncoDNA has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Bio Sequence.
Investment portfolio details for OncoDNA
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Diagnosis solutions for precision cancer medicine are developed.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for OncoDNA
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - OncoDNA
Detailed financials for OncoDNA
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncodna Comparisons
Peer comparison for OncoDNA
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OncoDNA
OncoDNA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Inscripta, MiRagen, Poseida Therapeutics and Juno Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Speech recognition solutions are provided by Inscripta for healthcare professionals.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
Detailed competitors of OncoDNA
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncodna
Complete news archive for OncoDNA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OncoDNA
OncoDNA was founded in 2012.
OncoDNA is headquartered in Charleroi, Belgium. It is registered at Charleroi, Walloon Region, Belgium.
OncoDNA is a funded company, having raised a total of $44.53M across 6 funding rounds to date.
OncoDNA was founded in 2012 and is based in Charleroi, Belgium. Operations focus on the oncology sector, where theranostic and genomic tools support precision medicine. Biomarker tests offered include OncoDEEP for therapeutic guidance, OncoSELECT as a liquid biopsy for monitoring and treatment, and OncoFOLLOW for tracking tumor progression. An NGS interpretation platform called OncoKDM and a biomarker test platform named OncoSHARE are also provided.
OncoDNA's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
OncoDNA offers OncoDEEP Kit, OncoSELECT Kit, OncoCDI, and OncoKDM.
OncoDNA has made 1 acquisition, including Bio Sequence.
OncoDNA has 16 investors. Key investors include Copenhagen Airport, Swisscanto, Ackermans & van Haaren, European Union, and SFPIM.